Hepatitis C Treatment Experiences and Decision Making Among Patients Living with HIV Infection

Overview

Journal J Assoc Nurses AIDS Care

Specialties Infectious Diseases
Nursing

Date 2009 Oct 27

PMID 19853480

Citations 10

Authors

Carol Bova

Lisa Fink Ogawa

Susan Sullivan-Bolyai

Affiliations

Soon will be listed here.

Abstract

Hepatitis C infection is a major problem for approximately 250,000 HIV-infected persons in the United States. Although HIV infection is well-controlled in most of this population, they suffer liver-associated morbidity and mortality. Conversely, hepatitis C virus (HCV) treatment uptake remains quite low (15%-30%). Therefore, the purpose of this qualitative study was to explore HCV treatment experiences and decision making in adults with HIV infection. The study sample included 39 coinfected adults; 16 in the HCV-treated cohort (who were interviewed a maximum of 3 times) and 23 in the HCV-nontreatment cohort. Analysis of interviews identified 2 treatment barriers (fears and vicarious experiences) and 4 facilitating factors (experience with illness management, patient-provider relationships, gaining sober time, and facing treatment head-on). Analysis of these data also revealed a preliminary model to guide intervention development and theoretical perspectives. Ultimately, research is urgently needed to test interventions that improve HCV evaluation and treatment uptake among HIV-infected patients.

Citing Articles

Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences.

Shumway M, Luetkemeyer A, Peters M, Johnson M, Napoles T, Riley E AIDS Care. 2019; 31(11):1340-1347.

PMID: 30829533 PMC: 6722022. DOI: 10.1080/09540121.2019.1587353.

Epidemiological Distribution and Genotype Characterization of the Hepatitis C Virus Among HIV Patients in Kashan, Iran.

Afzali H, Momen-Heravi M, Farokhzad A Hepat Mon. 2016; 16(7):e30459.

PMID: 27642343 PMC: 5018303. DOI: 10.5812/hepatmon.30459.

Patient capacity and constraints in the experience of chronic disease: a qualitative systematic review and thematic synthesis.

Boehmer K, Gionfriddo M, Rodriguez-Gutierrez R, Abu Dabrh A, Leppin A, Hargraves I BMC Fam Pract. 2016; 17:127.

PMID: 27585439 PMC: 5009523. DOI: 10.1186/s12875-016-0525-9.

Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment.

Zuchowski J, Hamilton A, Pyne J, Clark J, Naik A, Smith D BMC Gastroenterol. 2015; 15:124.

PMID: 26429337 PMC: 4591706. DOI: 10.1186/s12876-015-0356-5.

"Every drug goes to treat its own disease…" - a qualitative study of perceptions and experiences of taking anti-retrovirals concomitantly with anti-malarials among those affected by HIV and malaria in Tanzania.

Mangesho P, Reynolds J, Lemnge M, Vestergaard L, Chandler C Malar J. 2014; 13:491.

PMID: 25495956 PMC: 4302145. DOI: 10.1186/1475-2875-13-491.

References

Strathdee S, Patterson T . Behavioral interventions for HIV-positive and HCV-positive drug users. AIDS Behav. 2006; 10(2):115-30. DOI: 10.1007/s10461-005-9055-5. View

McNally S, Temple-Smith M, Sievert W, Pitts M . Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health. 2006; 30(5):422-7. DOI: 10.1111/j.1467-842x.2006.tb00457.x. View

Fink Ogawa L, Bova C . HCV treatment decision-making substance use experiences and hepatitis C treatment decision-making among HIV/HCV Coinfected Adults. Subst Use Misuse. 2009; 44(7):915-33. DOI: 10.1080/10826080802486897. View

Sherman K, Rouster S, Chung R, Rajicic N . Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002; 34(6):831-7. DOI: 10.1086/339042. View

Schackman B, Teixeira P, Weitzman G, Mushlin A, Jacobson I . Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree?. Med Decis Making. 2008; 28(2):233-42. DOI: 10.1177/0272989X07311753. View

Mohsen A, Easterbrook P, Taylor C, Portmann B, Kulasegaram R, Murad S . Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut. 2003; 52(7):1035-40. PMC: 1773713. DOI: 10.1136/gut.52.7.1035. View

Rifai M . Ethical impasses in the care of patients with hepatitis C. Psychosomatics. 2006; 47(6):540-1. DOI: 10.1176/appi.psy.47.6.540. View

Torriani F, Rodriguez-Torres M, Rockstroh J, Lissen E, Gonzalez-Garcia J, Lazzarin A . Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004; 351(5):438-50. DOI: 10.1056/NEJMoa040842. View

Grow J, Christopher S . Breaking the silence surrounding hepatitis C by promoting self-efficacy: hepatitis C public service announcements. Qual Health Res. 2008; 18(10):1401-12. DOI: 10.1177/1049732308322603. View

10.

Thomas D . The challenge of hepatitis C in the HIV-infected person. Annu Rev Med. 2008; 59:473-85. DOI: 10.1146/annurev.med.59.081906.081110. View

11.

Sulkowski M, Thomas D . Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis. 2005; 40 Suppl 5:S263-9. DOI: 10.1086/427440. View

12.

Selik R, Byers Jr R, Dworkin M . Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002; 29(4):378-87. DOI: 10.1097/00126334-200204010-00009. View

13.

Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S . Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis. 2000; 183(1):134-7. DOI: 10.1086/317644. View

14.

Khokhar O, Lewis J . Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?. Dig Dis Sci. 2007; 52(5):1168-76. DOI: 10.1007/s10620-006-9579-1. View

15.

Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R . Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001; 32(3):492-7. DOI: 10.1086/318501. View

16.

Mehta S, Thomas D, Sulkowski M, Safaein M, Vlahov D, Strathdee S . A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS. 2005; 19 Suppl 3:S179-89. DOI: 10.1097/01.aids.0000192088.72055.90. View

17.

Sulkowski M, Benhamou Y . Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007; 14(6):371-86. PMC: 1974798. DOI: 10.1111/j.1365-2893.2006.00816.x. View

18.

Sulkowski M, Moore R, Mehta S, Chaisson R, Thomas D . Hepatitis C and progression of HIV disease. JAMA. 2002; 288(2):199-206. DOI: 10.1001/jama.288.2.199. View

19.

Sandelowski M . Whatever happened to qualitative description?. Res Nurs Health. 2000; 23(4):334-40. DOI: 10.1002/1098-240x(200008)23:4<334::aid-nur9>3.0.co;2-g. View

20.

Weber R, Sabin C, Friis-Moller N, Reiss P, El-Sadr W, Kirk O . Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006; 166(15):1632-41. DOI: 10.1001/archinte.166.15.1632. View